Regenxbio INC. (RGNX) — 10-Q Filings

10-Q Filings (6)

• REGENXBIO Narrows 9-Month Loss Amid Soaring Royalty Revenue — Nov 6, 2025 Risk: high
  REGENXBIO Inc. reported a net loss of $61.941 million for the three months ended September 30, 2025, a slight increase from the $59.597 million net loss in the
• REGENXBIO's Q2 Loss Widens Amid Rising R&D Costs — Aug 7, 2025 Risk: high
  REGENXBIO Inc. reported a net loss of $70.8 million for the three months ended June 30, 2025, a significant increase from the $57.1 million net loss in the prio
• REGENXBIO Files Q1 2025 10-Q — May 12, 2025 Risk: medium
  REGENXBIO Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data and operational details
• REGENXBIO Q3 Update: $574.8M Cash, R&D Spends Rise — Nov 6, 2024 Risk: medium
  REGENXBIO Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash, cash equivalents, and marketable securities totaling $574.8 m
• REGENXBIO Inc. Files Q2 2024 10-Q Report — Aug 1, 2024 Risk: medium
  REGENXBIO Inc. filed its 10-Q for the period ending June 30, 2024. The company's fiscal year ends on December 31st. Key financial data and business activities f
• REGENXBIO Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
  REGENXBIO Inc. (RGNX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. REGENXBIO Inc. reported its financial results for the quarter ended March 31,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX